Considering the oxidative burden that is associated with cancer [57], the increased mutational rate in fetal relative to postnatal hematopoiesis [58], and given the comparatively already high oxidation levels we found on fetal HSPC proteins, fetal proteins that show redox sensitivity to a leukemia initiating mutation may be compelling therapeutic targets. Here, PSMA7 is linked to leukemia.